(Q37589638)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19719457%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

review article

1 reference

title

Current status of thalidomide and CC-5013 in the treatment of metastatic prostate cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19719457%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

0 references

William Douglas Figg, Sr.

series ordinal

4

object named as

William D Figg

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19719457%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1

Tristan M Sissung

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19719457%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

author name string

Silja Thordardottir

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19719457%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Erin R Gardner

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19719457%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

language of work or name

1 reference

1 December 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19719457%20AND%20SRC:MED&resulttype=core&format=json

Anti-Cancer Agents in Medicinal Chemistry

6 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19719457%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19719457%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19719457%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

page(s)

1058-1069

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19719457%20AND%20SRC:MED&resulttype=core&format=json

Multiple signals converging on NF-kappaB.

6 February 2020

cites work

1 reference

12 December 2020

A double-blind study of the sedative effects of the thalidomide enantiomers in humans

1 reference

12 December 2020

Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis

1 reference

12 December 2020

Tumor necrosis factor-alpha-induced apoptosis in prostate cancer cells through inhibition of nuclear factor-kappaB by an IkappaBalpha "super-repressor"

1 reference

12 December 2020

Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer.

1 reference

12 December 2020

Intravenous formulations of the enantiomers of thalidomide: pharmacokinetic and initial pharmacodynamic characterization in man.

1 reference

12 December 2020

Cytokine variations in patients with hormone treated prostate cancer

1 reference

12 December 2020

Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity

1 reference

12 December 2020

A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer.

1 reference

12 December 2020

The role of cyclooxygenase-2 in prostate cancer

1 reference

12 December 2020

Clinical pharmacology of thalidomide.

1 reference

12 December 2020

Thalidomide and its analogues inhibit lipopolysaccharide-mediated Iinduction of cyclooxygenase-2.

1 reference

12 December 2020

Thalidomide: 40 years on.

1 reference

12 December 2020

5'-OH-thalidomide, a metabolite of thalidomide, inhibits angiogenesis.

1 reference

12 December 2020

Tumor necrosis factor or tumor promoting factor?

1 reference

12 December 2020

Effects of putative hydroxylated thalidomide metabolites on blood vessel density in the chorioallantoic membrane (CAM) assay and on tumor and endothelial cell proliferation

1 reference

12 December 2020

Thalidomide metabolism by the CYP2C subfamily.

1 reference

12 December 2020

New aspects of natural-killer-cell surveillance and therapy of cancer

1 reference

12 December 2020

Effects of thalidomide, cytochrome P-450 and TNF-alpha on angiogenesis in a three-dimensional collagen gel-culture

1 reference

12 December 2020

Elevation of cytokine levels in cachectic patients with prostate carcinoma

1 reference

12 December 2020

Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide.

1 reference

12 December 2020

An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer.

1 reference

12 December 2020

Thalidomide metabolites in mice and patients with multiple myeloma

1 reference

12 December 2020

Principles of interleukin (IL)-6-type cytokine signalling and its regulation

1 reference

12 December 2020

Current status of thalidomide and its role in the treatment of metastatic prostate cancer

1 reference

12 December 2020

THALIDOMIDE IN THE TREATMENT OF LEPRA REACTIONS

1 reference

12 December 2020

A novel hypothesis for thalidomide-induced limb teratogenesis: redox misregulation of the NF-kappaB pathway

1 reference

12 December 2020

Metabolism of thalidomide in liver microsomes of mice, rabbits, and humans

1 reference

12 December 2020

Comparative molecular field analysis and comparative molecular similarity indices analysis of thalidomide analogues as angiogenesis inhibitors

1 reference

12 December 2020

Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer

1 reference

12 December 2020

Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice

1 reference

12 December 2020

Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer

1 reference

12 December 2020

Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium

1 reference

12 December 2020

Thalidomide pharmacokinetics and metabolite formation in mice, rabbits, and multiple myeloma patients

1 reference

12 December 2020

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

12 December 2020

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

12 December 2020

Tubulin-polymerization inhibitors derived from thalidomide

1 reference

12 December 2020

Expression of interleukin-8 gene in radical prostatectomy specimens is associated with advanced pathologic stage

1 reference

12 December 2020

Thalidomide and immunomodulatory drugs in the treatment of cancer

1 reference

12 December 2020

Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate

1 reference

12 December 2020

Interleukin-6 regulation of prostate cancer cell growth

1 reference

12 December 2020

Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma.

1 reference

12 December 2020

Distinct cytokine patterns exist in peripheral blood mononuclear cell cultures of patients with prostate cancer

1 reference

12 December 2020

Angiogenesis inhibitors derived from thalidomide

1 reference

12 December 2020

[Clinical evaluation of four cytokines in serum and prostatic fluid in chronic abacterial prostatitis]

1 reference

12 December 2020

Importance of the stress kinase p38alpha in mediating the direct cytotoxic effects of the thalidomide analogue, CPS49, in cancer cells and endothelial cells.

1 reference

12 December 2020

Thalidomide metabolism and hydrolysis: mechanisms and implications

1 reference

12 December 2020

Docetaxel and thalidomide as a treatment option for androgen- independent, nonmetastatic prostate cancer

1 reference

12 December 2020

Thalidomide destabilizes cyclooxygenase-2 mRNA by inhibiting p38 mitogen-activated protein kinase and cytoplasmic shuttling of HuR.

1 reference

12 December 2020

Thalidomide induces limb deformities by perturbing the Bmp/Dkk1/Wnt signaling pathway

1 reference

12 December 2020

Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer.

1 reference

12 December 2020

Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer

1 reference

12 December 2020

HIF-1 and NF-kappaB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells

1 reference

12 December 2020

Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma

1 reference

12 December 2020

Prostate inflammation and its potential impact on prostate cancer: a current review

1 reference

12 December 2020

Interplay of nuclear factor-kappaB and B-myb in the negative regulation of androgen receptor expression by tumor necrosis factor alpha

1 reference

12 December 2020

Thalidomide analogues as anticancer drugs

1 reference

12 December 2020

Recent advances in analytical determination of thalidomide and its metabolites

1 reference

12 December 2020

Circulating endothelial cells as a therapeutic marker for thalidomide in combined therapy with chemotherapy drugs in a human prostate cancer model

1 reference

12 December 2020

Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy

1 reference

12 December 2020

Cancer statistics, 2008

1 reference

12 December 2020

The role of angiogenesis inhibitors in prostate cancer.

1 reference

12 December 2020

Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation

1 reference

12 December 2020

Enzymatic resolution and evaluation of enantiomers of cis-5'-hydroxythalidomide

1 reference

12 December 2020

ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel

1 reference

12 December 2020

TNF-alpha/IL-1/NF-kappaB transduction pathway in human cancer prostate

1 reference

12 December 2020

A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation.

1 reference

12 December 2020

Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality

1 reference

12 December 2020

Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents.

1 reference

12 December 2020

Lenalidomide: a novel anticancer drug with multiple modalities

1 reference

12 December 2020

Synthesis, configurational stability and stereochemical biological evaluations of (S)- and (R)-5-hydroxythalidomides.

1 reference

12 December 2020

Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation

1 reference

12 December 2020

Phase I study of oral lenalidomide in patients with refractory metastatic cancer

1 reference

12 December 2020

Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients.

1 reference

12 December 2020

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

1 reference

12 December 2020

Induction of haptotactic migration of melanoma cells by neutrophil activating protein/interleukin-8.

1 reference

12 December 2020

Chemical structure and teratogenic properties. 3. A review of available data on structure-activity relationships and mechanism of action of thalidomide analogues.

1 reference

12 December 2020

Chromatographic separation of racemic thalidomide and teratogenic activity of its enantiomers (author's transl)

1 reference

12 December 2020

Macrophages and angiogenesis

1 reference

12 December 2020

Thalidomide is an inhibitor of angiogenesis

1 reference

12 December 2020

Topography of neovascularity in human prostate carcinoma

1 reference

12 December 2020

Chemical induction of interleukin-8, a proinflammatory chemokine, in human epidermal keratinocyte cultures and its relation to cytogenetic toxicity

1 reference

12 December 2020

Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma

1 reference

12 December 2020

Embryotoxic effects of thalidomide derivatives in the non-human primate callithrix jacchus. IV. Teratogenicity of micrograms/kg doses of the EM12 enantiomers

1 reference

12 December 2020

Elevated IL-8 production by trauma patients' monocytes is associated with elevated secretion of TNF alpha

1 reference

12 December 2020

Enantioselective inhibition of TNF-alpha release by thalidomide and thalidomide-analogues

1 reference

12 December 2020

Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization

1 reference

12 December 2020

Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells

1 reference

12 December 2020

TNF-alpha increases expression of IL-6 and ICAM-1 genes through activation of NF-kappaB in osteoblast-like ROS17/2.8 cells

1 reference

12 December 2020

Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells

1 reference

12 December 2020

Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents

1 reference

12 December 2020

Pharmacokinetics of thalidomide in an elderly prostate cancer population

1 reference

12 December 2020

10.2174/187152009789735017

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19719457%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19719457%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

PubMed publication ID

19719457

1 reference